The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Hypereosinophilic syndromes
Open accessAbstract
Hypereosinophilic syndromes (HES) constitute a rare and heterogeneous group of disorders, defined as persistent and marked blood eosinophilia (> 1.5 x 10(9)/L for more than six consecutive months) associated with evidence of eosinophil-induced organ damage, where other causes of hypereosinophilia such as allergic, parasitic, and malignant disorders have been excluded. Prevalence is unknown. HES occur most frequently in young to middle-aged patients, but may concern any age group. Male predominance (4-9:1 ratio) has been reported in historic series but this is likely to reflect the quasi-exclusive male distribution of a sporadic hematopoietic stem cell mutation found in a recently characterized disease variant. Target-organ damage mediated by eosinophils is highly variable among patients, with involvement of skin, heart, lungs, and central and peripheral nervous systems in more than 50% of cases. Other frequently observed complications include hepato- and/or splenomegaly, eosinophilic gastroenteritis, and coagulation disorders. Recent advances in underlying pathogenesis have established that hypereosinophilia may be due either to primitive involvement of myeloid cells, essentially due to occurrence of an interstitial chromosomal deletion on 4q12 leading to creation of the FIP1L1-PDGFRA fusion gene (F/P+ variant), or to increased interleukin (IL)-5 production by a clonally expanded T cell population (lymphocytic variant), most frequently characterized by a CD3-CD4+ phenotype. Diagnosis of HES relies on observation of persistent and marked hypereosinophilia responsible for target-organ damage, and exclusion of underlying causes of hypereosinophilia, including allergic and parasitic disorders, solid and hematological malignancies, Churg-Strauss disease, and HTLV infection. Once these criteria are fulfilled, further testing for eventual pathogenic classification is warranted using appropriate cytogenetic and functional approaches. Therapeutic management should be adjusted to disease severity and eventual detection of pathogenic variants. For F/P+ patients, imatinib has undisputedly become first line therapy. For others, corticosteroids are generally administered initially, followed by agents such as hydroxycarbamide, interferon-alpha, and imatinib, for corticosteroid-resistant cases, as well as for corticosteroid-sparing purposes. Recent data suggest that mepolizumab, an anti-IL-5 antibody, is an effective corticosteroid-sparing agent for F/P-negative patients. Prognosis has improved significantly since definition of HES, and currently depends on development of irreversible heart failure, as well as eventual malignant transformation of myeloid or lymphoid cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothenberg, M. E., & Hogan, S. P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090720 · Cited by 1,356
FAUCI, A. S., HARLEY, J. B., ROBERTS, W. C., FERRANS, V. J., GRALNICK, H. R., & BJORNSON, B. H. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-1-78 · Cited by 823
Anti-IL-5 and hypereosinophilic syndromes
SUTTON, S., ASSAAD, A., & ROTHENBERG, M. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.02.006 · Cited by 40
Cited by
Greco, A., Rizzo, M. I., De Virgilio, A., Gallo, A., Fusconi, M., Ruoppolo, G., Altissimi, G., & De Vincentiis, M. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.12.004 · Cited by 293
Metadata
- Authors
- Roufosse, F. E., Goldman, M., & Cogan, E.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2007-09-11
- Volume
- 2
- Issue
- 1
- Pages
- 37-37
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W4242989281
- Cited by
- 170
- References
- 3
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypereosinophilic syndromes. https://app.cochat.ai/papers/10.1186/1750-1172-2-37
- The paper
- Roufosse, F. E., Goldman, M., & Cogan, E. (2007). Hypereosinophilic syndromes. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-2-37
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.